NewAmsterdam Pharma Company (NAMS)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from NAMS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from NewAmsterdam Pharma Company's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $103M | $14M | $46M | $23M |
| Net income | -$42M | -$23M | -$177M | -$242M | -$204M |
| Free cash flow | -$30M | $10M | -$141M | -$159M | -$148M |
| EPS (diluted) | -$3.81 | -$1.19 | -$2.15 | -$2.56 | -$1.72 |
| Operating margin | — | -3.5% | -1298.6% | -386.9% | -1002.9% |
Superinvestors who own NAMS
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by NewAmsterdam Pharma Company's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Michael H. Davidson Chief Executive Officer |
10,000 | $22.65 | $226,500 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when NAMS trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are NewAmsterdam Pharma Company insiders buying the stock?
1 open-market insider purchase of NAMS in the last 12 months, from SEC Form 4 filings.
Companies like NewAmsterdam Pharma Company
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.